Y-mabs announces proposed public offering of common stock

New york, feb. 16, 2021 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab), a commercial stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the commencement of a registered underwritten public offering of up to $100 million in shares of its common stock. all shares in the offering are expected to be offered by the company. in addition, the company intends to grant the underwriters a 30-day option to purchase up to $15 million in shares of its common stock.
YMAB Ratings Summary
YMAB Quant Ranking